Ascendis Pharma price target raised to $295 from $289 at Wells Fargo

Wells Fargo raised the firm’s price target on Ascendis Pharma (ASND) to $295 from $289 and keeps an Overweight rating on the shares. The firm thinks shares should trade up +5%-10% on the strong Q2. In the near-term, removal of the MBX overhang should further lift shares as U.S. Yorvipath launch revenues continue to ramp significantly – it’s not too late to own this launch, Wells adds.